Company Analysis Gyre Therapeutics, Inc.
1. Summary
Advantages
- Price (16.79 $) is less than fair price (21.63 $)
- Current debt level 0.351% is below 100% and has decreased over 5 years from 1.83%.
- The company's current efficiency (ROE=587.14%) is higher than the sector average (ROE=0%)
Disadvantages
- Dividends (0%) are below the sector average (0%).
- The stock's return over the last year (-51.54%) is lower than the sector average (-35.79%).
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Gyre Therapeutics, Inc. | Index | ||
|---|---|---|---|
| 7 days | 11.8% | -18.5% | 1.9% |
| 90 days | -2.4% | -11.6% | 7.6% |
| 1 year | -51.5% | -35.8% | 28.6% |
GYRE vs Sector: Gyre Therapeutics, Inc. has significantly underperformed the "" sector by -15.75% over the past year.
GYRE vs Market: Gyre Therapeutics, Inc. has significantly underperformed the market by -80.11% over the past year.
Stable price: GYRE is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: GYRE with weekly volatility of -0.9911% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (16.79 $) is lower than the fair price (21.63 $).
Price significantly below the fair price: The current price (16.79 $) is 28.8% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is higher than that of the sector as a whole (0).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (49.05).
4.3. P/BV
P/BV vs Sector: The company's P/BV (140.07) is higher than that of the sector as a whole (0).
P/BV vs Market: The company's P/BV (140.07) is higher than that of the market as a whole (3.18).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (17.22) is higher than that of the sector as a whole (0).
P/S vs Market: The company's P/S indicator (17.22) is higher than that of the market as a whole (10.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (16.55) is higher than that of the sector as a whole (0).
EV/Ebitda vs Market: The company's EV/Ebitda (16.55) is lower than that of the market as a whole (28.35).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 198.67% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (198.67%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0%).
5.4. ROE
ROE vs Sector: The company's ROE (587.14%) is higher than that of the sector as a whole (0%).
ROE vs Market: The company's ROE (587.14%) is higher than that of the market as a whole (10.67%).
5.5. ROA
ROA vs Sector: The company's ROA (-79.74%) is lower than that of the sector as a whole (0%).
ROA vs Market: The company's ROA (-79.74%) is lower than that of the market as a whole (6.44%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.5.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
